Onc Club | Videos

Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

October 14th 2021

Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Dr. Roychowdhury on Future Research Directions With FGFR Inhibitors in Cholangiocarcinoma

October 14th 2021

Sameek Roychowdhury, MD, PhD, discusses future research directions with FGFR inhibitors in patients with cholangiocarcinoma.

Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in Oncology

August 30th 2021

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology

August 30th 2021

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Scott on the Rationale to Evaluate GARD-Based Radiotherapy Dosing in Oncology

August 18th 2021

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Labaki on Disparities in Mammography Screenings During the COVID-19 Pandemic

August 9th 2021

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

Dr. Trinh on the Recovery of Cancer Screening Tests Following First COVID-19 Pandemic Peak

August 9th 2021

Quoc-Dien Trinh, MD, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic. 

Dr. Halmos on the Efficacy of COVID-19 Vaccines in Patients With Cancer

June 25th 2021

Balazs Halmos, MD, discusses the efficacy of the COVID-19 vaccines in patients with cancer.

Dr. Landgren on the Clinical Impact of KRd-D in Multiple Myeloma

May 13th 2021

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.

Dr. Maura on the Significance of Studying Myeloma Genomic Defining Events

April 26th 2021

Francesco Maura, MD, discusses the significance of studying genomic defining events in patients with multiple myeloma.

Dr. Landgren on the Rationale For Examining Whole Genome Sequencing in Smoldering Myeloma

April 26th 2021

Ola Landgren, MD, PhD, discusses the rationale behind examining whole-genome sequencing in smoldering myeloma.

Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia Vera

March 30th 2021

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Dr. Abu-Zeinah on Investigating Interferon-Alpha in Polycythemia Vera

March 19th 2021

Ghaith Abu-Zeinah, MD, discusses utilizing interferon-alpha in patients with polycythemia vera.

Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the Caribbean

March 18th 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United States

March 18th 2021

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Dr. Choueiri on the CheckMate-9ER Exploratory Analysis in Advanced RCC

March 18th 2021

Toni K. Choueiri, MD, discusses results from an exploratory analysis of the phase 3 CheckMate-9ER trial in patients with advanced renal cell carcinoma.

Dr. Motzer on the Efficacy of Cabozantinib in RCC

March 18th 2021

Robert J. Motzer, MD, discusses the efficacy of cabozantinib in patients with renal cell carcinoma.